| Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ... New England journal of medicine 384 (5), 403-416, 2021 | 11282 | 2021 |
| Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation D Wrapp, N Wang, KS Corbett, JA Goldsmith, CL Hsieh, O Abiona, ... Science 367 (6483), 1260-1263, 2020 | 10456 | 2020 |
| An mRNA vaccine against SARS-CoV-2—preliminary report LA Jackson, EJ Anderson, NG Rouphael, PC Roberts, M Makhene, ... New England journal of medicine 383 (20), 1920-1931, 2020 | 3760 | 2020 |
| Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... Nature 593 (7857), 130-135, 2021 | 2397 | 2021 |
| Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults EJ Anderson, NG Rouphael, AT Widge, LA Jackson, PC Roberts, ... New England Journal of Medicine 383 (25), 2427-2438, 2020 | 1738 | 2020 |
| SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... Nature 586 (7830), 567-571, 2020 | 1631 | 2020 |
| Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555, 2020 | 1238 | 2020 |
| Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen J Pallesen, N Wang, KS Corbett, D Wrapp, RN Kirchdoerfer, HL Turner, ... Proceedings of the National Academy of Sciences 114 (35), E7348-E7357, 2017 | 1172 | 2017 |
| Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus JS McLellan, M Chen, MG Joyce, M Sastry, GBE Stewart-Jones, Y Yang, ... science 342 (6158), 592-598, 2013 | 1090 | 2013 |
| Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine RA Seder, LJ Chang, ME Enama, KL Zephir, UN Sarwar, IJ Gordon, ... Science 341 (6152), 1359-1365, 2013 | 987 | 2013 |
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination N Pardi, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, ... Nature 543 (7644), 248-251, 2017 | 974 | 2017 |
| Rapid COVID-19 vaccine development BS Graham Science 368 (6494), 945-946, 2020 | 943 | 2020 |
| Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody JS McLellan, M Chen, S Leung, KW Graepel, X Du, Y Yang, T Zhou, ... Science 340 (6136), 1113-1117, 2013 | 919 | 2013 |
| Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo AW Rimoin, PM Mulembakani, SC Johnston, JO Lloyd Smith, NK Kisalu, ... Proceedings of the National Academy of Sciences 107 (37), 16262-16267, 2010 | 896 | 2010 |
| Animal models for COVID-19 C Muñoz-Fontela, WE Dowling, SGP Funnell, PS Gsell, AX Riveros-Balta, ... Nature 586 (7830), 509-515, 2020 | 884 | 2020 |
| Pre-fusion structure of a human coronavirus spike protein RN Kirchdoerfer, CA Cottrell, N Wang, J Pallesen, HM Yassine, HL Turner, ... Nature 531 (7592), 118-121, 2016 | 876 | 2016 |
| Durability of responses after SARS-CoV-2 mRNA-1273 vaccination AT Widge, NG Rouphael, LA Jackson, EJ Anderson, PC Roberts, ... New England Journal of Medicine 384 (1), 80-82, 2021 | 855 | 2021 |
| Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19 N Doria-Rose, MS Suthar, M Makowski, S O’Connell, AB McDermott, ... New England Journal of Medicine 384 (23), 2259-2261, 2021 | 733 | 2021 |
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ... New England Journal of Medicine 369 (22), 2083-2092, 2013 | 724 | 2013 |
| Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection HM Yassine, JC Boyington, PM McTamney, CJ Wei, M Kanekiyo, ... Nature medicine 21 (9), 1065-1070, 2015 | 705 | 2015 |